계명대학교 의학도서관 Repository

Comparison of Resolute zotarolimus-eluting and Xience everolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES VI trial

Metadata Downloads
Author(s)
Sung-Ho HerWeon KimMyung Ho JeongJoo-Young YangBong-Ki LeeHun Sik ParkDuk-Woo ParkSeung-Jung ParkDo-Yoon KangCheol Hyun LeePil Hyung LeeJung-Min AhnSeung-Whan LeeYoung-Hak KimSeong-Wook ParkChang Wook NamYun Seok ChoiSeung-Woon RhaJang Hyun Cho
Keimyung Author(s)
Nam, Chang Wook
Department
Dept. of Internal Medicine (내과학)
Journal Title
Coronary Artery Disease
Issued Date
2019
Volume
30
Issue
1
Keyword
angioplastycoronary diseasestents
Abstract
Background
Outcomes for stent-based coronary intervention of lesions with long diseased segments remain relatively unfavorable. This study sought to compare the efficacy of Resolute zotarolimus-eluting stents (R-ZES) and Xience everolimus-eluting stents (EES) for very long coronary lesions.

Methods and results
This randomized, multicenter, prospective trial compared the use of R-ZES with EES for very long (≥50 mm) native coronary lesions. The primary end point was in-segment late luminal loss at 12-month angiographic follow-up. A total of 400 patients were needed to assess the primary end point. However, owing to very slow enrollment of patients, this trial was early terminated (302 patients were enrolled), and thus, this report provides descriptive information on primary and secondary end points. The R-ZES and EES groups had similar baseline characteristics. Lesion length was 49.6± 10.2 and 50.6± 13.3mm in the R-ZES and EES groups, respectively (P=0.47). The number of stents used at the target lesion was 2.1 ±0.3 and 2.2± 0.5, respectively. Twelve-month angiographic follow-up was performed in 50% of eligible patients. In-segment late luminal loss did not significantly differ between the R-ZES and EES groups (0.17 ± 0.57 vs. 0.09 ± 0.43 mm, P=0.32). In-segment binary restenosis rates were 8.1 and 5.3% in the R-ZES and EES groups, respectively (P=0.49). There were no significant betweengroup differences in the rate of adverse events (death, myocardial infarction, stent thrombosis, target lesion revascularization, and composite outcomes).

Conclusion
For patients with very long native coronary artery disease, R-ZES and EES implantation showed comparable angiographic and clinical outcomes through 1 year of follow-up.
Keimyung Author(s)(Kor)
남창욱
Publisher
School of Medicine (의과대학)
Citation
Sung-Ho Her et al. (2019). Comparison of Resolute zotarolimus-eluting and Xience everolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES VI trial. Coronary Artery Disease, 30(1), 59–66. doi: 10.1097/MCA.0000000000000680
Type
Article
ISSN
1473-5830
Source
https://insights.ovid.com/pubmed?pmid=30507632
DOI
10.1097/MCA.0000000000000680
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41894
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.